REVIVA ANNOUNCES PUBLICATION ON CLINICAL VOCAL BIOMARKER DATA FROM THE RECOVER PHASE 3 CLINICAL TRIAL OF BRILAROXAZINE TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

Reuters · 4d ago

Please log in to view news